Thalia Therapeutics plc (AIM:THAT) CEO Dr David Solomon joined Proactive's Stephen Gunnion to discuss the acquisition of Sanmirna Therapeutics and how it transforms Thalia into a clinical-stage RNA therapeutics business.
The deal brings clinical-stage asset miRisten into Thalia's portfolio, adding a Phase 1 trial currently recruiting AML patients at City of Hope. miRisten targets miR-126, a microRNA associated with disease progression. Solomon explained that reducing it may slow AML while making leukaemia stem cells more susceptible to existing treatments such as Venetoclax and chemotherapy.
The acquisition advances Thalia's timeline by more than seven years compared with developing a similar asset in-house, with top-line trial results expected by H1 2027 and interim data before that. "This deal transforms Thalia into a clinical stage company overnight," he said.
A £2.75 million fundraise alongside the deal is expected to fund the trial through to readout, with strong backing from directors, vendors and institutional investors.
The interview also covers Thalia's broader pipeline, including its cardiovascular gene-silencing programme and the Nuvec delivery technology.
For more interviews and market insights, visit the Proactive YouTube channel. Please like this video, subscribe to the channel and enable notifications so you never miss future content.
#ThaliaTherapeutics #DavidSolomon #miRisten #AML #AcuteMyeloidLeukaemia #RNAtherapeutics #MicroRNA #Biotech #HealthcareInvesting #AIMMarket #ClinicalTrials #CityOfHope #DrugDevelopment #GeneSilencing #LifeSciences
